English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMost surgeons would choose mesh for a hypothetical SUI surgery, while treatment choices for POP are mixed, according to the report by William J. Devan, MD, of Maine Medical Center, Portland, and colleagues. They write, “Overall, we hope that the implications of the study findings will help to lessen the negative stigma associated with overall mesh use.”
Specialists would opt for mesh surgery for SUI – but not transvaginal POP repair
Polypropylene mesh has long been used in surgery for pelvic floor disorders, but there is a history of concerns over the safety of these materials. Beginning in 2008, the FDA issued a series of alerts warning of rare but potentially serious complications related to the use of mesh to treat SUI and POP. Although these complications can occur in many types of mesh procedures, they appear most common after transvaginal (surgery performed via the vagina), as opposed to abdominal surgery.
Subsequent data suggested that serious complications are “not rare” in women undergoing transvaginal mesh procedures for POP. In 2019, the FDA ordered mesh products for transvaginal procedures for POP to be permanently removed from the market. Meanwhile, “sling” procedures using mesh materials are regarded as safe and effective, and are still the most common type of surgical treatment for SUI.
Given this long and complex history, what are the opinions of the experts who perform these procedures? Dr. Devan and colleagues surveyed members of two leading specialty societies: the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) and the American Urogynecologic Society (AUGS). These experts were presented with a list of options for managing SUI and POP and asked which treatment they would choose, if making the decision for themselves.
For SUI, 69% of surgeons said they would opt for a mesh procedure – specifically, a mid-urethral sling procedure using polypropylene mesh. The remaining surgeons said they would choose one of five other options, one of which was “no treatment.” There were some differences in opinion among different subgroups. For example, surgeons who performed a high volume of procedures were more likely to say they would opt for a mesh mid-urethral sling procedure, if undergoing treatment for SUI.
In contrast, there was no clear single choice for treatment of POP. Most surgeons said they would opt for conventional abdominal surgery with mesh or vaginal pelvic floor reconstruction using their own native tissues.
Thus the views of the surgical specialists “seem to align” with the FDA’s recommendations supporting mesh use for SUI – but against transvaginal mesh for POP. Dr. Devan and colleagues conclude, “We hope that if patients learn that the surgeons who perform these operations would opt for mesh when used appropriately, the patients might view it more favorably.”
DOI: 10.1097/UPJ.0000000000000307
###
About Urology Practice
An Official Journal of the American Urological Association (AUA), Urology Practice focuses on clinical trends, challenges and practice applications in the four areas of Business, Health Policy, the Specialty and Patient Care. Information that can be used in everyday practice will be provided to the urology community via peer-reviewed clinical practice articles (including best practices, reviews, clinical guidelines, select clinical trials, editorials and white papers), “research letters” (brief original studies with an important clinical message), the business of the practice of urology, urology health policy issues, urology education and training, as well as content for urology care team members.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
